BiotechTube

Ketorolac + Prochlorperazine + Diphenhydramine

Phase 2Terminated
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Headache, Migraine

Conditions

Headache, Migraine

Trial Timeline

Jan 1, 2024 → Dec 31, 2025

NCT ID
NCT06083571

About Ketorolac + Prochlorperazine + Diphenhydramine

Ketorolac + Prochlorperazine + Diphenhydramine is a phase 2 stage product being developed by Assertio Holdings for Headache, Migraine. The current trial status is terminated. This product is registered under clinical trial identifier NCT06083571. Target conditions include Headache, Migraine.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06083571Phase 2Terminated

Competing Products

20 competing products in Headache, Migraine

See all competitors
ProductCompanyStageHype Score
Placebo + LY2300559Eli LillyPhase 2
52
Aricept (donepezil hydrochloride)EisaiPhase 2
52
Galcanezumab 300 mg + PlaceboEli LillyPhase 3
77
GalcanezumabEli LillyPhase 3
77
Galcanezumab-GnlmEli LillyApproved
85
LY2590443 + Placebo injection + Sumatriptan + Placebo capsuleEli LillyPhase 2
52
LY2951742 + PlaceboEli LillyPhase 2
52
Galcanezumab + PlaceboEli LillyPhase 3
77
Galcanezumab + PlaceboEli LillyPhase 2
52
Soy IsoflavonesJohnson & JohnsonPre-clinical
23
topiramateJohnson & JohnsonPhase 3
77
Ubrogepant 50 MG [Ubrelvy] + Ubrogepant 100 MG [Ubrelvy]AbbVieApproved
85
Placebo + Zolmitriptan + Zolmitriptan + ZolmitriptanAstraZenecaApproved
85
candesartan cilexetil + placeboAstraZenecaPhase 2
52
Rizatriptan + PlaceboMerckPre-clinical
23
Propranolol or nadolol + Placebo control + Optimal Acute TherapyMerckApproved
85
AMG 334NovartisPhase 2
52
SOM230 + PlaceboNovartisPhase 2
52
ErenumabAmgenPhase 2
51
Erenumab + Ethynil Estradiol/Norgestimate Oral ContraceptiveAmgenPhase 1
32